Atopic Dermatitis Clinical Trials Market To Reach $4.84 Billion By 2030

Atopic Dermatitis Clinical Trials Market Growth & Trends

The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period.    

For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth.

Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions.

Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis.

 Request a free sample copy or view report summary: Atopic Dermatitis Clinical Trials Market Report

Atopic Dermatitis Clinical Trials Market Report Highlights

• Large molecules dominated the molecule type segment with a 53.2% share in 2023 due to the increasing pipeline of biologics penetrating the atopic dermatitis clinical trials industry.

• Interventional trials dominated the market owing to the large number of clinical trials with interventional study designs.

• Phase III category by phase segment is anticipated to hold the highest market share in 2023. This is due to the increasing number of drugs undergoing phase III studies. Moreover, the cost of phase III studies is much higher than the other phases, contributing to the largest market share.

• North America dominated the market owing to factors such as increasing the prevalence of atopic dermatitis in the region, presence of major market players in the region, government support for quality healthcare, and availability of reimbursement.

Atopic Dermatitis Clinical Trials Market Segmentation

Grand View Research has segmented the atopic dermatitis clinical trials market on the basis of molecule type, study design, phase and region:

Atopic Dermatitis Clinical Trials Molecule Type Outlook (Revenue, USD Million; 2018 - 2030)

• Small molecules

• Large Molecules

Atopic Dermatitis Clinical Trials Study Design Outlook (Revenue, USD Million; 2018 - 2030)

• Interventional

• Observational

Atopic Dermatitis Clinical Trials Phase Outlook (Revenue, USD Million; 2018 - 2030)

• Phase I

• Phase II

• Phase III

• Phase IV

Atopic Dermatitis Clinical Trials Region Outlook (Revenue, USD Million; 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Thailand

  • South Korea

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Atopic Dermatitis Clinical Trials Market

• Charles River Laboratories

• Imavita    

• REPROCELL Inc.

• Oncodesign services

• BIOCYTOGEN

• QIMA LTD

• Novotech

• Redoxis

• Syneos Health

• Hooke Laboratories, LLC